Eliglustat [Cerdelga™ (US, EU)], a small-molecule oral glucosylceramide analogue that inhibits the enzyme glucosylceramide synthase has been developed by Genzyme Corporation (a subsidiary of Sanofi) for the treatment of Gaucher disease type 1 in adults. Inhibition of this enzyme reduces the accumulation of the lipid glucosylceramide in the liver, spleen, bone marrow and other organs. Eliglustat received its first global approval in this indication in the US, for use in treatment-naïve and treatment-experienced adult patients. It is also under regulatory review in the EU and Japan. This article summarizes the milestones in the development of eliglustat leading to this first approval for Gaucher disease type 1.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Weinreb NJ. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2013;11(Suppl 1):77–90.
Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182–93.
Szer J. The substrate is down: is the IV out? Blood. 2010;116(6):860–1.
Shayman JA. Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs Future. 2010;35(8):613–20.
Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46–60.
Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 1993;82(5):1402–9.
Rosenberg M, Kingma W, Fitzpatrick MA, et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 1999;93(6):2081–8.
US Food and Drug Administration. FDA approves new drug to treat a form of Gaucher disease [media release]. 19 Aug 2014.
Genzyme Corporation. CERDELGA (eliglustat) Prescribing Information. 2014. http://cerdelga.com/pdf/cerdelga_prescribing_information.pdf. Accessed 15 Sept 2014.
Genzyme Corporation. FDA Grants Priority Review for Genzymes Cerdelga(Tm) (eliglustat), an Investigational Oral Therapy for Gaucher Disease [media release]. 11 Dec 2013.
Genzyme Corporation. FDA Approves Genzymes Cerdelga(Tm) (eliglustat) Capsules [media release]. 19 Aug 2014.
Sanofi. Sanofi: solid sales and business EPS growth at CER [media release]. 31 July 2014. http://sanofi.mediaroom.com/2014-07-31-Sanofi-Solid-Sales-and-Business-EPS-Growth-at-CER.
Sanofi. Sanofi Q3 2013 Marks the End of the Patent Cliff Period [media release]. 30 Oct 2013.
Sanofi-Aventis. Sanofi-Aventis Completes Acquisition of Genzyme Corporation [media release]. 8 Apr 2011.
Sanofi. United States Securities and Exchange Commission Washington, DC 20549 FORM 20-F (2012). 2013. http://www.sanofi.com/Images/31972_20-F_2012_V2.pdf. Accessed 05 Sept 2014.
Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695–705.
Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893–9.
Hard ML, Puga AC, Ross L, et al. A phase 1 study evaluating the effect of eliglustat on the pharmacokinetics, safety and tolerability of digoxin in healthy subjects [abstract no. 1384434]. Clin Pharmacol Drug Dev. 2012;1(4):176.
Packman S, Amato D, Dasouki M, et al. ENGAGE: A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1 (GD1): 9 month results [abstract no. 2276F]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston.
Dasouki M, Lukina E, Ben Dridi MF, et al. Effects of oral eliglustat on bone disease in Gaucher disease type 1: Results from the randomized, placebo-controlled engage trial [abstract no. P-597]. J Inherit Metab Dis. 2013;36(2 SUPPL. 1):S268.
Burrow TA, Balwani M, Cox TM, et al. Encore: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals [abstract no. 3468]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7 December 2013: New Orleans.
Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095–8.
Lukina E, Peterschmitt J, Watman N, et al. Eliglustat tartrate, a novel investigational oral substrate reduction therapy for gaucher disease type 1: updated phase 2 results [abstract no. 3791]. In: Blood Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).
Puga AC, Lukina E, Watman N, et al. Biomarker responses after 3 years of treatment with eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1) [abstract no. P-375]. J Inherit Metab Dis. 2011;34(Suppl 3):S202.
Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for gaucher disease type 1: phase 2 results after 4 years of treatment [abstract no. 1038]. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).
Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 results after 3 years [abstract no. 1104]. In: Blood Conference: 53rd Annual Meeting of the American Society of Hematology, ASH. 2011;118(21).
Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014. doi:10.1007/s00256-014-1891-9.
Mankoski R, Taylor JS, Marulkar S, et al. Clinical response to eliglustat in treatment-naive patients with gaucher disease type 1: post hoc comparison to imiglucerase in a real-world setting [abstract no. 130]. In: American College of Medical Genetics Annual Clinical Genetics Meeting; 25 May 2014: Nashville.
Mankoski R, Peterschmitt J, Puga AC, et al. The adverse event profile of eliglustat for the treatment of gaucher disease type 1: results from a pooled analysis of four trials [abstract no. 2275T]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston.
Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease who have reached therapeutic goals with enzyme replacement therapy (ENCORE) [ClinicalTrials.gov identifier NCT00943111]. US National Intitutes of Health, ClinicalTrials.gov. 2009. http://clinicaltrials.gov/ct2/show/NCT00943111?term=eliglustat&rank=7. Accessed 03 Sept 2014.
Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease (ENGAGE) [ClinicalTrials.gov identifier NCT00891202]. US National Institutes of Health, ClinicalTrials.gov. 2009. http://clinicaltrials.gov/ct2/show/NCT00891202?term=eliglustat&rank=4. Accessed 03 Sept 2014.
Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease to evaluate once daily versus twice daily dosing (EDGE) [ClinicalTrials.gov identifier NCT01074944]. US National Institutes of Health, ClinicalTrials.gov. 2010. http://clinicaltrials.gov/ct2/show/NCT01074944?term=eliglustat&rank=6. Accessed 03 Sept 2014.
Genzyme Corporation. A study of the efficacy and safety of eliglustat tartrate (Genz-112638) in type 1 gaucher patients [ClinicalTrials.gov identifier NCT00358150]. US National Institutes of Health, ClinicalTrials.gov. 2006. http://clinicaltrials.gov/ct2/show/NCT00358150?term=eliglustat&rank=5. Accessed 03 Sept 2014.
This profile has been extracted and modified from the Adis R&D Insight drug pipeline database. Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.
About this article
Cite this article
Poole, R.M. Eliglustat: First Global Approval. Drugs 74, 1829–1836 (2014). https://doi.org/10.1007/s40265-014-0296-3
- Enzyme Replacement Therapy
- Liver Volume
- Lumbar Spine Bone Mineral Density
- Dabigatran Etexilate